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U6jectives. This study was desim to mvestigte whether 
combination therapy with metoprolol and nifedipine provides a 
greater anti-is&en& effect than does moaothetupy in individual 
patients uitb stable au&a pectotis. 
Boc$pound. Combiition tmapy with a btbadre- block- 
ingagent(wblchreducesmyoearditlloxygenconum@m)anda 
dibylropyridine ad&m antagonist (wi@ inaeases coronmy blood 
Row)isalogiealapptuxchtothebeatmentofstubletingbmpeeqarir 
HouvewF,itisnddearwhether,iaiodivictualpptieats,this~bieed 
therapy is more e&ctive than mono&upy. 
4feU. ‘hvo bumbed eighty patients with stuble an&us pectoris 
were enrolled iu a double-blind trbd in 25 Euqeuu centers. Patients 
wemnlndomkwd(week0)to~(Qnttrolledrelease,200nlg 
onceduily)ors&dipine(Retatd,2Omgtwice~)fer6~ 
plaeeboorthealtenuuivedrugwasthenuddedforalurtber4ue&. 
Exedse~werepwtonaedat~Q6aod IO. 
l&u&. At week 6, both metoprolol and nifedipine increased 
the mean exercise titoe to l-turn ST segment depression in 
comparison with week 0 (both p < 0.01); metoprolol was more 
Stable angina pectoris is characterized by transient ischemic 
episodes due to a discrepancy between myocardial oxygen 
supply and demand. Beta-adrenergic blocking agents, which 
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effective than nifedipine (p < 0.05). At week 10, the groups 
n-mdomixed to combinatiou therapy bad a further increase in time 
to l-mm ST segment depression (p C 0.05 vs. placebo). Analysis 
of the results iu indiidual patients revealed tbat 7 (11%) of 63 
patients adding nifedipine to metopndol and 17 (2996) of 59 
puttents (p c 0.0091) uddiug metoprolol to nifedipbx showed an 
iucrease in exercise tolerance that was greater than the 90th 
percentile of the distributiou of tbe changes observed in the 
correspondhsg monotherapy t placebo groups. However, amoug 
these patients. mt additive e&et was observed only in 1(14%) of 
the 7 patierts treated with metoprolol t aifedipine and in 4 (24%) 
of tbe 17 treated wfth nifedipine + metoprolol. 
tTLvIe~~.mmean¶dd&ive¶n-efectslmwnby 
cotDbh&m~witltmetoprdol¶ndnitodipisci¶p¶oentswitb 
st&lemr&~¶pectodsisnottberrsultofanadditive~in 
indhidna! patits. lbtber, it may be attributed to the mcruitment 
bytbesemIddnigofp¶tientsnotrespondito-py. 
(J Am Con Cam%9 19%;27:311-6) 
reduce oxygrr .r,nsumption, and dihydropyridine calcium an- 
~ag(;‘k!s, *vhich act mainly by increasing coronary blood flow, 
may be considered two opposing pharmacologic approaches to 
prevent transient myocardial ischemia in this setting. and their 
antianginal e5cacy has been shown in several controlled 
clinical trials. Because of their complementary mode of action, 
beta-blockers and dihydropyridine calcium antagonists are 
often used in combination to reduce angina1 symptoms and 
increase exercise tolerance. However, it is not clear whether 
this combination therapy has more anti-ischemie effect than 
that of monotherapy with either agent. Among the studies 
comparing the antianginai e&&s of combined versus monc- 
therapy, only a few (l-4) have ken adequate in design, and 
none had enough power to clarify this issue, which remains a 
matter of debate (5-8). In some studies (1,4), indeed, com- 
bined treatment with metoprolol or propranolol and nifedipine 
has led to a significant inmase in mean exercise tolerance in 
comparison with monotherapy. However, no study has reported 
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Figure 1. Study design. Numbers in paren- 
theses indicate the number of patients in- 
cluded in the per-protocol analysis. s.1. 
NTG = sublingual nitroglycerin; R = ran- 
domization. *Time of exercise testing and 
hospital visits. 
weeks -2 0 2 4 6 
-tests * * 
olmy cards 
Vi&S * * * * 
whether the additive effect observed in the combination group 
was due to a summation of the anti-ischemic effects of both 
drugs in individual patients or to an increase in exercise 
tolerance ‘with the second drug in non-responders to mono- 
therapy. The International Multicenter AnGina Exercise study 
:Jb XGE) was designed to address this issue, which has clear 
cliniral relevance. because combined antianginal therapy is 
warranted only in those patients receiving a significant anti- 
ischemic effect from both drugs. 
Methods 
Patient selection. For this multicenter trial, 290 patients 
with chronic stable angina pectorit. were enrolled in 25 Euro- 
pean centers. To qualify for the study, the patients had to 
report typical angina1 symptoms that had been stable for ~6 
months and show a positive response to exercise stress testing. 
with 23 min of exercise tolerance. The exclusion criteria 
included age >75 years, recent (<6 months) myocardial 
infarction, heart failure and angina of such severity that even 
temporary withdrawal of antianginal therapy was not feasible. 
Patients Gith serious concomitant diseases, including obstruc- 
tive lung disease and insulin-dependent diabetes mellitus, or 
with hemoglobin levels ~11 g/d1 or systolic blood pressure 
<lOO mm Hg, were also excluded. Only patients with sinus 
rhythm who had an analyzable ST segment on electrocardio- 
graphy were included. 
Study pr&oeoJ (PJ 1). After the patients gave informed 
consent, all previous cardiovascular medications were gradu- 
aUy discontinued over a 2-week placebo run-in period during 
which only sublingual nitroglycerin was allowed (for interrup- 
tion of anginal attacks). At the end of this period (week 0), a 
bat :line symptom-limited exercise test was performed and the 
patients were randomly allocated to double-blind treatment 
for 6 weeks with either metoprolol (controlled release, 200 mg 
o~lce daily) or nifedipine (Retard, 20,mg tablets twice daiJy) 
6 10 
* 
* 
according to a parallel group design. After this period, the 
metoprolol-treated patients were further randomized to the 
addition of placebo or nifedipine for a further 4 weeks, and the 
nifedipine-treated patients were assigned to the addition of 
placebo or metoprolol. Both randomizations were decided at 
week 0. The study was conducted in blinded fashion with use of 
the double-dummy technique (i.e., throughout the study, in- 
cluding the run-in period, patients took 3 tablets/day of either 
metoprolol at MO A.M. nifedipine at 8:OO AM and at 8:OO PM or 
the corresponding placebos). At the end of both the mono- 
therapy and combined therapy periods (week 6 and week lo), 
exercise tests were repeated according to the same protocol 1 
to 4 h after morning drug intake. To standardize data collec- 
tion and exercise testing, a member of the steering committee 
visited all participating centers during the planning phase of 
the study. The study was conducted in accordance with the 
Declarations of Helsinki and Tokyo, and the protocol was 
approved by the Ethics Committee of each participating 
center. 
Diary cards. Throughout the study, the patients recorded 
the occurrence of anginal attacks on diary cards that were 
collected at the end of the run-in period and after 6 and 10 
weeks of double-blind treatmenl. The mean weekly number of 
angina1 attacks was,calculated for each patient for the run-in 
period and the final 2 weeks of both the monotherapy and 
combined, therapy periods. Compliance with the therapeutic 
regimen was evaluated at each visit by counting the number of 
returned tablets. Good compliance was defined as 80% to 
120% of scheduled tablet consumption. 
Exercise test. Bicycle exercise tests were performed at an 
initial work load of 30 W, which was subsequently increased by 
10 W every minute. A standard 1Zlead electrocardiogram 
(ECG) and blood pressure levels were Iecorded immediately 
before the start of the test, and at 1-min intervals during 
exercis and for at least the 1st 10 min of the recovery phase. 
The exercise test was stopped,at the occurrence of moderate to 
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severe angina, dyspnea, exhaustion or ST segment depression 
>3 mm. Horizontal or downsloping ST segment depression 
>O.l mV for 0.08 s after the J point, with or without chest pain, 
was considered to demonstrate a positive exercise test result. 
The time to l-mm ST segment depression was used to define 
patients’ ischemic threshold. For the subsequent exercise tests 
performed during treatment, total exercise time was used as an 
ersatz end-point in patients who did not show :,I-mm ST 
segment depression (9). 
Statistical analysis. Statistical analysis was performed 01, 
the data of the 249 patients completing the study (per protocol 
analysis). The absolute difference in time to l-mm ST segment 
depression from week 6 to week 10 was the main efficacy 
variable. The group data are reported as mean values with 95% 
confidence intervals. To analyze the effect of combined therapy 
in individual patients, the 90th percentile of the distribution of 
the changes in time to l-mm STsegment depression from week 
6 to week 10 observed in the pooled placebo groups was 
arbitrarily considered the upper limit of spontaneous variabil- 
ity in our study patients. This limit was found to be 144 s and 
corresponded to a 33% increase in time to I-mm ST segment 
depression over the mean values observed at week 6. Patients 
in the combination groups whose change in time to l-mm ST 
segment depression from week 6 to week 10 was >144 s were 
considered to have had a true pharmacologic effect during the 
combination phase of the study. The proportions of such 
patients were compared between combination groups by using 
the chi-square test. In these patients, the presence of an 
additive anti-ischemic effect of combined therapy was investi- 
gated by analyzing the changes in time to l-mm ST segment 
depression from week 0 to week 6 (monotherapy phase). An 
additive anti-ischemic effect was considered tr) have occurred 
in patients whose change in time to l-mm C, i’ szgm”ut depres- 
sion during monotherapy exceeded the 50th percentile of the 
distribution of the changes observed in the respective mono- 
therapy group. 
participate because of increased angina during the run-in 
phase, 2 who did not satisfy inclusion criteria and 2 who were 
excluded for unknown reasons). Two hundred eighty patients 
entered the double-blind phase; 249 completed the study, 
whereas 31 dropped out: Compliance was considered good in 
95% of the patients and did not differ among treatment groups. 
Table 1 shows the baseline characteristics of tne patients 
completing the study, classified by randomization group. 
Thirty-five percent of the patients were in New York Heart 
Association functional class II, 58% in class ill and 7% in class 
IV. with an equal distribution among the randomization groups 
Effect of treatment on angina tkequeney (Table 2). Com- 
plete diary card data were obtained from 240 of the 249 
patients completing the study. In comparison with week 0, 
there was a similar significant reduction in angina frequency 
with both metoprolol and nifedipine at the end of the mono- 
therapy period. During the combination part of the study, a 
further significant reduction (p < 0.05) in angina frequency 
was observed in the group adding metoprolol to nifedipine, 
whereas no significant changes were observed for the other 
groups. However, at week 10, angina frequency did not differ 
among groups. 
Results 
Effect of treatment on exercise toieraoce. At the end of the 
run-in period, the patients showed a wide range of exercise 
tolerance at l-mm ST segment depression (Fig. 2). In compar- 
ison with baseline, both metoprolol and nifedipine increased 
the mean exercise time to l-mm ST segment depression at 
week 6 (both p < 0.01); improvement was significantly greater 
in the patients receiving metoprolol (p < 0.05) (Table 3). At 
week 10, there was no further change in exercise tolerance in 
either group in which placebo was added to the original 
monotherapy, but the combination of the hvo active drugs led 
to a considerable increase in mean exercise tolerance (p < 0.05 
vs. placebo). During combination therapy, the mean effects of 
metoprclol added to nifedipine (64 s, p < 0.05 vs. week 6) and 
of nifedipine added to metoprolol (35 s, p = 0.07 vs. week 6) 
were of approximately the same magnitude as those observed 
with the two drugs during monotherapy (73 and 43 s. respec- 
tively) (Table 3). 
Patient characteristics and outcome. Of the 290 enrolled Seven patients (11%) in the metoprolol t nifedipine group 
patients, 10 were not randomized (6 who were unwilling to and 17 (29%) in the nifedipine f metoprolol group (p < 
Table 1. Demographic and Baseline E&&se Test Characteristics of All Patients Included in Per-Protocol Analysis 
Me!opndol t Placebo Metoproloi t Nifedipine Nifedipine + Placebo Nlfedipine + Me~oprold 
(n = hS) (ll =h3) (n = h?) (II = 59) 
Age (YO 59 : :: jY + R Ml -r 8 59 1 Y 
Gender (M/F) 56’9 53’10 :;:.:I 45 I4 
Hypert~llSMl-8 II 7 a b 
Diihetes 3 3 4 
Smukem 41 3x 37 31 
Previous myccardial infarction 4 4 x 7 
Previous antianginal medtc&ms .1x 3Y 3-s -3 
AnginaI episode&k (no. of episodes) 5.7 2 7 5.2 L 5 S.4 2 h 7.1 ‘4 
Time IO I-mm ST depression (s) 35x r lhx 386% 162 3x2 2 I48 31 f I-44 
Total exercise time (s) 489 c 115 52u f 1x5 532 i I55 .l%r 135 
Unless otherwise indicated, values are expressed as mean value 2 SD or numkr of patients. F = female: M = male. 
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Table 2. Effect of Treatment on Weekly Number of Angina1 Attacks 
Week 6 
Mean A 
95% Cl 
Week 6 
Mean A 
95% Cl 
Week IO 
Mean A 
95% CI 
Metoprolol (n = 122) 
- 1.95 
- 1.2!, 10 -2.64 
k4etoprolol t Placebo Metoprolol t Niledipine 
(n = 61) (n = 61) 
-1.93 -- 1.91 
-0.78 to -3.07 -1.16 to -2.19 
-2.01 --Lo6 
-0.82 to -3.19 -1.11 to -3.02 
Nifedipine (n = 118) 
-1.57 
-0.69 to -2.45 
Nifcdipine + Placebo Ndedipine + Metoprolol 
(n =- 61) (n = 57) 
-ml.77 - 1.36 
-0.57 to -2.96 -0.04 10 -2.69 
-2.32 -2.71 
-0.70 to -3.93 - 1.93 to -?.80 
%a are expressed as mean change from number of attacks at baseline (Mean S) and 95% confidence inten% (Cl). Values at week 6 are reported according 1o 
monotherapy groups (ahove) and comhinarion groups (below). Baseline values arc reporled in Table 1. 
0.0001) showed an increase in time to l-mm ST segment 
deptesiion from week 6 to week 10 that was greater than the 
90th percentile of the distribution of the changes observed in 
the corresponding monotherapy + placebo groups. The great 
majority of these patients had responded poorly to mono- 
therapy. In fact, of the 24 patients showing a true pharmaco- 
logic effect during the combination phase of the study, only 1 
(14%) of 7 in the group adding nifedipine to metoprolol and 4 
(24%) of 17 in the group adding metoprolol to nifedipine, 
showed changes in time to l-mm ST segment depression 
during monotherapy of above the 50th percentile of the 
distribution of the changes observed in the corresponding 
monotherapy group, thus demonstrating the additive anti- 
ischemic effect of metoprolol and nifedipine. 
Safety. The safety data base of the IMAGE study refers to 
2,692 patient-weeks-l,133 with metoprolol, 1,055 with nifed- 
ipine and 504 with combination treatment. Table 4 shows the 
reasons for patient dropout classified acmIding to the catego- 
ries of cardiovascular events, side effects and non-drug-related 
causes. There werk 14 cardiovascular events including 1 sud- 
den death. 3 acute myocardial infarctions, 8 cases of unstable 
angina, 1 of syncope and 1 of stroke. The incidence of these 
events did not differ among treatment groups. Ten patients 
(3.5% of the total study group) ,dropped out of the study 
because of drug-related side effects that were among those 
expected from metoprolol and nifedipine. No patient withdrew 
because of side effects during combination therapy. 
Discussion 
Ratioaale for aad clinkal efficacy of combination therapy 
with metoproiol and nifedipine in stable angina pectoris. 
Patients with stable angina pectoris experience episodei of 
myocardial ischemia due to a transient discrepancy between 
myocardial oxygen demand and supply. in the present study, 
we considered metoprolol and nifedipine to be the prototypes 
of two opposing, and possibly complementary, approaches 
aimed at preventing an imbalance between oxygen supply and 
demand. In fact, the main meehinism of action of metoprolol 
is to reduce myocardial oxygen consumption through its effect 
on heart rate and contractility, whereas nifedipine predomi- 
nantly increases coronary blood flow by inhibiting vasomotor 
tone at the site of eccentric stenoses and at the level of the 
precapillary sphincters (10). Several placebo-controlled trials 
(l&12) have shown that both metoprolol and nifedipine are 
effective antianginal agents. The present study in a large group 
of patients with stable angina pectoris confirms that both drugs 
increase exercise tolerance and reduce angina frequency, 
metoprolol significantly more effectively tha,, nifedipine. 
Because the two agents act predominantly on different 
determinants of the supply/demand ratio, their combination 
has been considered a logical second step in patients who 
remain symptomatic ot continue to show a positive exercise 
test response despite treatment with a single agent. This 
approach has been favored by the results of clinical trials 
(1,4,6) showing that the combination of a beta-blocker and 
nifedipine increases exercise tolerance over that achieved with 
monotherapy. Similarly, the present study shows that, or 
average, when the two drugs are used ir. combination, the 
Figure 2. Patient distribution according to the time ,o I-mm ST 
segment depression during the exercise test perform?! P’ the end of 
thr run-in period. 
1 
1il-i 
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Table 3. Effect of Treatment on Time to I-mm ST Segment Depresll7r 
Metoprolol (n = 128) Ntfedipine (n = 121) 
Week 6 
Mean increase 
95% CI 
70 43 
41-92 16-69 
Metoprolol t Placebo Metoprolol t Nifedipine Nifedipine t Placeho Nitcdipine + Mctoprolol 
(n = 65) (n = 63) (n = 62) (n = S9) 
Week 6 
Mean increase 66 73 43 43 
95% Cl 34-98 40-107 h-i? 5-80 
Week 10 
Mean increase 49 108 37 107 
95% Cl 17-80 71-145 l-72 M-151 
Data are expressed as mean increase (in seconds) from baseline time to l-mm ST segment depression. Values at week 6 arc reported according to monotherapy 
(above) and combination groups (below). Baseline values are reported in Table 1. 
prcioirgation of mean exercise tolerance is the sum of that 
obtained with metoprolol and nifedipine during monotherapy. 
TOP Urge sample size of the IMAGE study also allowed us 
to investigate whether this additive effect could be demon- 
strated at an individual level. Surprisingly, the proportion of 
patients with increased exercise tolerance after both mono- 
therapy and combination therapy was small. Most of the 
additional effect observed in the groups receiving combination 
therapy was the result of an increase in exercise tolerance in 
patients who had not had such an increase during mono- 
therapy; this recruitment effect was particularly evident in 
patients adding metoprolol to nifedipine. A partial explanation 
for the lack of additive effect in individual patients may be that 
both metoprolol and nifedipine have, in addition to their main 
antianginal mechanisms, other effects that may favorably affect 
the oxygen supply/demand ratio (8). A beta,-selective blocker 
such as metoprolol may also improve coronary blood flow by 
prolonging coronary diastolic fillirtg time and by redistributing 
flow to the ischemic subendo-cardial regions; nifedipine may 
also reduce left ventricular afterload, thus decreasing oxygen 
consumption. Finally, both agents can improve ventricular 
relaxation, which may further enhance subendocardial blood 
flow. Hence, metoprolol and nifedipine appear to reduce 
myocardial &hernia by a variety of similar mechanisms that 
may not be additive in individual patients. 
In the present study, we considered the effect of metoprolol 
and nifedipine on exercise tolerance to be the most reliable 
measure of drug efficacy; we did not investigate the effect of 
combination therapy on angina! symptoms in individual pa- 
tients. In some way, the mean effect on angina1 symptoms 
mimicked the mean effect on exercise tolerance, because only 
the group adding metoprolol to nifedipine had a significant 
reduction in angina frequency. However, in contrast to the 
exercise test data, no differences in angina frequency between 
combination and monotherapy were observed at the end of the 
study. This discrepancy between the effects of drugs on ECG 
ischemia and on symptoms has been shown in other studies 
(13,14) and in the lMAGE study (15). In addition, the 
standardized therapy with metoprolol and nifedipine used in 
the IMAGE study reduced angina frequency from a mean of 5 
to 7 attacks/week at the end of the run-in period to an average 
of 3 to 4 attacks/week at the end of the study; thus, most 
patients continued to have a disturbing frequency of angina1 
attacks after therapy. 
Table 4. Reasons for Withdrawal From Study 
Cardiovascular Events Side Effects Non-Drug Rclatcd 
Metoprolol Sudden death (1) Itching (I) Pbaryngitis (I) 
Myocardial infarction (1) Depression (1) Poor compliance (I) 
Unstable angina (3) Diuinesr (I ) 
Stroke (1) 
SY”W (1) 
Nifedipine Myoeardial infarction (1) Palpitation (3) Eitc::vc coronaD surgery (1) 
Unstable angina (2) Gitric pain 11) Leg pain (I) 
Headache ( I J 
Diiiness (1) 
Ankle edema (1) 
Combined therapy Myocardiil infarction (1) Noncardiac surgery (2) 
Unstable angina (3) Poor compliance (1) 
Numbers in parentheses indiiate the number of patients with tbe condition. For each patient. only the main reason 
for withdrawal is listed. 
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A kqical alternative to combined therapy would be to’select 
the most effective drug for each individual patient and to titrate 
the dosage until exercise-induced ischemia disappears, the patient 
becomes asymptomatic during daily life or the maximal tolerated 
dosage is reached. Unfortunately, it is not easy to predict the best 
pharmacologic approach for an individual patient as a previous 
report of the IMAGE study (16) showed that the characteristics 
of angina1 symptoms and the results of exercise testing do not 
predii a preferential effect of metoprolol or nifedipine (except in 
patients with vey low exercise tolerance, who seem to benefit 
more from the beta-blocker). 
2. Kostuk WJ, Pflugfelder P. Comparative ekcts of calcium entry-blocking 
drugs. pblocking drugs. and their combination in patients with chronic 
stable angina. Circulation lY87;75 Suppl V:V-114-21. 
3. Akhras F. Jackson G. Efficacy of nifedipine and isosorbide mononitrate in 
combination with atenolol in stable angina. Lancet lYY1;338:1036-9. 
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IYY?;ty:409-17. 
Sat%ty of q ifedipine, metopmlol and their combination in 
stable angina pectoris. The safety data base of the IMAGE 
study is reassuring in view of the recent reports of the possible 
proischemic effect of dihydropyridine calcium antagonists 
(17-19). In fact, during a period of more than 1,000 
patient-weeks of treatment with 20 mg twice daily of mono- 
therapy with nifedipine in the classical Retard formulation, 
no excess of proischemic complications was observed in 
comparison with those reported with metoprolol. This pos- 
itive result may be attributed to the relatively low dosage of 
nifedipine and to the fact that the Retard formulation seems 
to elicit little, if any, reflex tachycardia. The combination of 
metoprolol and nifedipine was also well tolerated. Because 
the IMAGE study encompassed a broad spectrum of patients 
with stable angina pectoris ranging from functional class II to IV 
and from a very low to good exercise tolerance, our tolerability 
data may represent a good example of what is likely to happen in 
the general population of patients with stable angina. 
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angina pectoris. J Cardiovasc Pharmacvl IYX7;ltl Suppl 2:S38-47. 
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